Immunovant, Inc. cotiza a 30.26 USD y tiene una capitalización bursátil de $6.3B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupu…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.68 | $-0.67 | $-0.54 |
| Estimado | $-0.72 | $-0.61 | $-0.63 | $-0.69 |
| Sorpresa | — | -11.5% | -6.3% | +21.7% |
| Métrica | IMVT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -59.3% | -40.4% | -18.9% |
| ROA | -52.8% | -32.0% | -20.8% |
| Current Ratio | 9.09 | 2.84 | +6.25 |
| Debt / Equity | — | 0.28 | — |